PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1

PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1

BackgroundEsophageal squamous cell carcinoma (ESCC) is an aggressive tumor with a 5-year survival rate of only 20%. More than 80% of ESCC patients possess TP53 mutation, which abolishes the G1/S checkpoint and accelerates the cell cycle. Thus, WEE1 and PKMYT1, regulators of G2/M phase in cell cycle,...

Full description

Bibliographic Details
Main Authors: Qingyi Zhang, Xu Lin, Kan Jiang, Jun Deng, Lei Ke, Ziheng Wu, Pinghui Xia, Qi Li, Li Yu, Pengzhi Ni, Wang Lv, Jian Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
PD0166285
esophageal squamous cell carcinoma
WEE1
PKMYT1
radiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1061988/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1061988/full

Similar Items